Abstracts Archive - Page 167 of 2607 - ACR Meeting Abstracts

Abstract Number: 0945 • ACR Convergence 2025
Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
Jorge Romo-Tena¹, Luz Blanco², Shuichiro Nakabo³, Victoria Hoffman⁴, Norio Hanata⁵, Mingzeng Zhang², Carmelo Carmona-Rivera⁵, Eduardo Patino-Martinez⁶, Dillon Claybaugh², Zu-Xi Yu² and Mariana Kaplan⁵, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²NIH, Bethesda, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁶NIH/NIAMS, Bethesda, MD
Background/Purpose: Nerve injury-induced protein-1 (Ninj1) is an adhesion molecule that plays various roles in immune and stromal cells, including the modulation of inflammation and a…
Abstract Number: 0915 • ACR Convergence 2025
A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
Yuhao Qin¹, Huan Wang¹, Han Gao¹, Chongqi Zhang¹, Chengpan Wang¹, yanru fan¹, wei ye¹, yuan lin¹, Lu Su², Wenming Ren¹ and cheng liao¹, ¹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), ²Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China
Background/Purpose: Pathological elevation of type I interferon (IFN-I) , B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) has been robustly documented across multiple autoimmune…
Abstract Number: 0983 • ACR Convergence 2025
Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Grace Frechette, Thamotharampillai Dileepan, Marc Jenkins and Shawn Mahmud, University of Minnesota, Minneapolis
Background/Purpose: Mixed connective tissue disease (MCTD) is a systemic autoimmune disorder marked by a U1-small nuclear ribonucleoprotein (U1-snRNP) autoantibody. The majority of U1-snRNP antibodies in…
Abstract Number: 0958 • ACR Convergence 2025
Asynchronous Resolution of Inflammation and Fibrosis in A Prolonged Experimental Model Suggests Distinct Temporal Dynamics And Resolution Mechanisms in Systemic Sclerosis
Aurore Collet¹, Manel Jendoubi², Thomas Guerrier², Alexis Largy², Silvia Speca², Sylvain Dubucquoi¹ and David Launay³, ¹Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Institut d’Immunologie, Lille, France, Lille, France, ²Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ – INFINITE – Institute for Translational Research in Inflammation, Lille, France, Lille, France, ³Univ. Lille, Inserm, CHU Lille, U¹²⁸⁶ – INFINITE – Institute for Translational Research in Inflammation, Lille, France ; CHU Lille, Département de Médecine interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille France, Lille, France
Background/Purpose: Systemic sclerosis (SSc) is characterized by tissue fibrosis, which is defined as excessive and irreversible extracellular matrix (ECM) accumulation, leading to organ dysfunction. In…
Abstract Number: 0002 • ACR Convergence 2025
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Brian Kim, Christine Lowe, Francisco Flores, Jeremy Margaitis, Alessandro Calo, Stacey Valny, Anna Konecny, Eva Jaghatspanyan, Sean Yoder, Kenneth Ertel, Simone Filosto, Jodi Murakami and David Barrett, Kite, a Gilead Company, Santa Monica, CA
Background/Purpose: B-cell dysregulation is a key factor in the development and progression of autoimmune diseases, and B-cell inhibition has been a cornerstone of treatment for…
Abstract Number: 0898 • ACR Convergence 2025
Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
Carley Tasker¹, Nicholas Giovannone², Nyanza Rothman², Sofia Caruso², Julia Provino², Laura Johnsen², Johanna Napetschnig², Jamie Orengo¹, Christos Kyratsous², Andre Limnander¹, Katherine Cygnar² and Andrew Baik², ¹Regeneron, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: Development of effective targeting strategies to eliminate sources of antibody production presents utility in the treatment of autoimmune diseases driven by pathogenic autoantibodies. Furthermore,…
Abstract Number: 0993 • ACR Convergence 2025
NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
Leah Huey¹, Emily Vance², Bryce Binstadt³ and Ruth Napier², ¹Oregon Health & Science University, Denver, CO, ²University of Colorado Anschutz, Aurora, CO, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Blau syndrome is a pediatric rheumatic disease characterized by dermatitis, arthritis, and uveitis. Blau syndrome is caused by inborn or de novo mutations in…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0909 • ACR Convergence 2025
Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Marcus Hines¹, Timothy Borbet² and Sergei Koralov², ¹New York University Grossman School of Medicine, New York, NY, ²NYU Langone Medical Center, New York
Background/Purpose: The microRNA(miR)29 family is encoded by two separate loci, the miR29ab1 and miR29b2c alleles. We have previously shown that the microRNA(miR)29 family regulates the…
Abstract Number: 0923 • ACR Convergence 2025
Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
Julia Rood¹, Stephanie Suh Kyung Yoon², Mary Heard¹, Michael Hogan², Nicola Ternette³, Edward Behrens⁴ and Laurence Eisenlohr¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Dundee, Dundee, Scotland, United Kingdom, ⁴CHOP, West Chester, PA
Background/Purpose: Viral infections and major histocompatibility complex class II (MHC II) are both implicated in the genesis of systemic lupus erythematosus (SLE), but a mechanistic…
Abstract Number: 0243 • ACR Convergence 2025
Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
Carmen Lasa Teja¹, Laura Muñoz-Llopis², Diana Prieto-Peña³, Isla Morante Bolado⁴, José Luis Martín-Varillas⁵, Nerea Paz-Gandiaga⁶ and Ricardo Blanco⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ⁵Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁶Rheumatology, Hospital Comarcal de Laredo, Laredo, Spain., Santander, ⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) are rare disorders characterized by recurrent episodes of fever, serositis, gastrointestinal symptoms, arthritis, and/or skin lesions. In adult-onset SAIDs, clinical…
Abstract Number: 1004 • ACR Convergence 2025
Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Yang Yang¹, Yusuke Miyashita², Madison Mangin³, Kellen Winden¹, Peter Nigrovic² and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Brookline, MA, ³Boston Children's Hospital, St Simons Island, GA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We…
Abstract Number: 1000 • ACR Convergence 2025
A Deep-Learning Based Approach Uncovers Novel Mediators of Micro-RNA Restraint of Type-2 Immunity
Shaan Sekhon¹, Robin Kageyama², Neil Sprenkle³, Hannah Happ², Eric Wigton², Heather Pua³ and Mark Ansel², ¹University of California, San Francisco, Berkeley, ²University of California, San Francisco, San Francisco, ³Vanderbilt University, Nashville
Background/Purpose: MicroRNAs, such as miR-24 and miR-27, co-expressed within the Mirc11 and Mirc22 clusters, orchestrate a regulatory network critical to Th2 cell differentiation and cytokine…
Abstract Number: 0919 • ACR Convergence 2025
Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
Stefanie Kurth¹, Andre Tiaden¹, Edveena Hanser¹, Simone Häner¹, Stavros Giaglis¹, Florian Geier¹, Dominik Burri¹, Katarzyna Buczak¹, Ute Heider², Stefan Wild², Yves Acklin¹, Christian Egloff¹ and Diego Kyburz³, ¹University of Basel, Basel, Switzerland, ²Miltenyi Biotec, Bergisch-Gladbach, Germany, ³University Hospital Basel, Basel, Switzerland
Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of…
Abstract Number: 0622 • ACR Convergence 2025
Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
Malvika Gupta¹ and Chander Raman², ¹Mayo Clinic, Rochester MN, Rochester, MN, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Shrinking Lung Syndrome (SLS) is a rare pulmonary complication of systemic lupus erythematosus (SLE), characterized by unexplained dyspnea, pleuritic chest pain, loss of lung…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].